S-1 in the treatment of pancreatic cancer

Table 7 Randomized phase III studies of adjuvant therapy in pancreatic cancer

Study	Treatment	Endpoint	n	DFS(mo)	MST(mo)
ESPAC-1[55]	CRT (5-FU + RT)	OS	145	10.7	15.9
	No CRT		144	15.2a	17.9
	5-FU + leucovorin		147	15.3c	20.1b
	No chemotherapy		142	9.4	15.5
CONKO-001[56]	GEM	DFS	179	13.4d	22.1
	Surgery alone		175	6.9	20.2
JSAP-02[58]	GEM	OS	58	11.4e	22.3
	Surgery alone		60	5.0	18.4
ESPAC-3[59]	GEM	OS	537	14.3	23.6
	5-FU + folinic acid		551	14.1	23.0
JASPAC-01[11,12]	GEM	OS	191	11.2	25.9
	S-1		187	23.2f	NAf

^aP < 0.05 vs CRT;

^cP < 0.05 vs No chemotherapy;

^bP < 0.01 vs No chemotherapy;

^dP < 0.01 vs Surgery alone;

^eP < 0.05 vs Surgery alone;

^fP < 0.01 vs GEM. DFS: Disease-free survival; MST: Median survival time; NA: Not available; OS: Overall survival; 5-FU: 5-fluorouracil.